Johnson & Johnson (JNJ) 8-K Results of Operations and Financial Condition

Exhibit 99.20

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)	FIRST QUARTER
	2009			2008			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$    15,026		100.0	$    16,194		100.0	(7.2)
Cost of products sold	4,251		28.3	4,614		28.5	(7.9)
Selling, marketing and administrative expenses	4,608		30.7	5,123		31.6	(10.1)
Research expense	1,518		10.1	1,712		10.6	(11.3)
Interest (income)expense, net	81		0.5	16		0.1
Other (income)expense, net	(75)		(0.5)	(18)		(0.1)
Earnings before provision for taxes on income	4,643		30.9	4,747		29.3	(2.2)
Provision for taxes on income	1,136		7.6	1,149		7.1	(1.1)
Net earnings	$      3,507		23.3	$      3,598		22.2	(2.5)
Net earnings per share  (Diluted)	$        1.26			$        1.26
Average shares outstanding  (Diluted)	2,789.8			2,866.3
Effective tax rate	24.5	%		24.2	%

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)	FIRST QUARTER
			Percent Change
	2009	2008	Total		Operations	Currency
Sales to customers by
segment of business
Consumer
U.S.	$  1,726	1,819	(5.1)	%	(5.1)	-
International	1,985	2,245	(11.6)		2.4	(14.0)
	3,711	4,064	(8.7)		(1.0)	(7.7)
Pharmaceutical
U.S.	3,674	4,070	(9.7)		(9.7)	-
International	2,106	2,359	(10.7)		2.8	(13.5)
	5,780	6,429	(10.1)		(5.1)	(5.0)
Med Devices & Diagnostics
U.S.	2,652	2,588	2.5		2.5	-
International	2,883	3,113	(7.4)		3.6	(11.0)
	5,535	5,701	(2.9)		3.1	(6.0)
U.S.	8,052	8,477	(5.0)		(5.0)	-
International	6,974	7,717	(9.6)		3.0	(12.6)
Worldwide	$ 15,026	16,194	(7.2)	%	(1.2)	(6.0)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)	FIRST QUARTER
			Percent Change
	2009	2008	Total		Operations	Currency
Sales to customers by
geographic area
U.S.	$  8,052	8,477	(5.0)	%	(5.0)	-
Europe	3,671	4,308	(14.8)		(0.2)	(14.6)
Western Hemisphere excluding U.S.	1,062	1,245	(14.7)		4.5	(19.2)
Asia-Pacific, Africa	2,241	2,164	3.6		8.5	(4.9)
International	6,974	7,717	(9.6)		3.0	(12.6)
Worldwide	$ 15,026	16,194	(7.2)	%	(1.2)	(6.0)

REPORTED SALES vs. PRIOR PERIOD
$MM
	FIRST QUARTER
					% Change
	2009		2008		Reported			Operational (1)			Currency
CONSUMER SEGMENT (2)
SKIN CARE
US		423		382		10.7	%		10.7	%		-
Intl		419		458		(8.5	%)		5.4	%		(13.9	%)
WW		842		840		0.2	%		7.8	%		(7.6	%)
BABY CARE
US		102		115		(11.3	%)		(11.3	%)		-
Intl		387		418		(7.4	%)		4.3	%		(11.7	%)
WW		489		533		(8.3	%)		0.9	%		(9.2	%)
ORAL CARE
US		188		199		(5.5	%)		(5.5	%)		-
Intl		177		187		(5.3	%)		11.6	%		(16.9	%)
WW		365		386		(5.4	%)		2.8	%		(8.2	%)
OTC/NUTRITIONALS
US		726		842		(13.8	%)		(13.8	%)		-
Intl		622		752		(17.3	%)		(2.4	%)		(14.9	%)
WW		1,348		1,594		(15.4	%)		(8.4	%)		(7.0	%)
WOMEN'S HEALTH
US		149		148		0.7	%		0.7	%		-
Intl		274		313		(12.5	%)		0.5	%		(13.0	%)
WW		423		461		(8.2	%)		0.7	%		(8.9	%)
WOUND CARE / OTHER
US		138		133		3.8	%		3.8	%		-
Intl		106		117		(9.4	%)		4.2	%		(13.6	%)
WW		244		250		(2.4	%)		4.0	%		(6.4	%)
TOTAL CONSUMER
US		1,726		1,819		(5.1	%)		(5.1	%)		-
Intl		1,985		2,245		(11.6	%)		2.4	%		(14.0	%)
WW		3,711		4,064		(8.7	%)		(1.0	%)		(7.7	%)
* See footnotes at end of document

REPORTED SALES vs. PRIOR PERIOD
$MM
	FIRST QUARTER
					% Change
	2009		2008		Reported			Operational (1)			Currency
PHARMACEUTICAL SEGMENT  (2)
ACIPHEX/PARIET
US		138		116		19.0	%		19.0	%		-
Intl		125		161		(22.4	%)		(8.4	%)		(14.0	%)
WW		263		277		(5.1	%)		3.0	%		(8.1	%)
CONCERTA
US		269		224		20.1	%		20.1	%		-
Intl		75		66		13.6	%		37.0	%		(23.4	%)
WW		344		290		18.6	%		23.9	%		(5.3	%)
DURAGESIC/FENTANYL TRANSDERMAL
US		75		75		0.0	%		0.0	%		-
Intl		156		158		(1.3	%)		12.6	%		(13.9	%)
WW		231		233		(0.9	%)		8.5	%		(9.4	%)
LEVAQUIN/FLOXIN
US		408		474		(13.9	%)		(13.9	%)		-
Intl		17		22		(22.7	%)		(3.1	%)		(19.6	%)
WW		425		496		(14.3	%)		(13.4	%)		(0.9	%)
PROCRIT/EXPREX
US		321		334		(3.9	%)		(3.9	%)		-
Intl		229		295		(22.4	%)		(10.0	%)		(12.4	%)
WW		550		629		(12.6	%)		(6.8	%)		(5.8	%)
RAZADYNE/REMINYL
US		13		50		(74.0	%)		(74.0	%)		-
Intl		88		99		(11.1	%)		5.1	%		(16.2	%)
WW		101		149		(32.2	%)		(21.5	%)		(10.7	%)
REMICADE
US		737		676		9.0	%		9.0	%		-
US Exports (4)		286		320		(10.6	%)		(10.6	%)		-
Intl		5		2		150.0	%		139.3	%		10.7	%
WW		1,028		998		3.0	%		3.0	%		-
RISPERDAL/RISPERIDONE
US		118		582		(79.7	%)		(79.7	%)		-
Intl		157		227		(30.8	%)		(24.6	%)		(6.2	%)
WW		275		809		(66.0	%)		(64.2	%)		(1.8	%)
RISPERDAL CONSTA
US		126		101		24.8	%		24.8	%		-
Intl		199		208		(4.3	%)		13.9	%		(18.2	%)
WW		325		309		5.2	%		17.5	%		(12.3	%)
TOPAMAX
US		495		520		(4.8	%)		(4.8	%)		-
Intl		107		126		(15.1	%)		0.1	%		(15.2	%)
WW		602		646		(6.8	%)		(3.8	%)		(3.0	%)
VELCADE
US		-		2		(100.0	%)		(100.0	%)		-
Intl		192		182		5.5	%		21.8	%		(16.3	%)
WW		192		184		4.3	%		20.5	%		(16.2	%)
OTHER
US		688		596		15.4	%		15.4	%		-
Intl		756		813		(7.0	%)		9.1	%		(16.1	%)
WW		1,444		1,409		2.5	%		11.8	%		(9.3	%)
				��
TOTAL PHARMACEUTICAL
US		3,674		4,070		(9.7	%)		(9.7	%)		-
Intl		2,106		2,359		(10.7	%)		2.8	%		(13.5	%)
WW		5,780		6,429		(10.1	%)		(5.1	%)		(5.0	%)
* See footnotes at end of document

REPORTED SALES vs. PRIOR PERIOD
$MM
	FIRST QUARTER
					% Change
	2009		2008		Reported			Operational (1)			Currency
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
PREZISTA
US		72		32		125.0	%		125.0	%		-
Intl		50		42		19.0	%		41.1	%		(22.1	%)
WW		122		74		64.9	%		77.3	%		(12.4	%)
INVEGA
US		66		57		15.8	%		15.8	%		-
Intl		25		9		177.8	%		221.8	%		(44.0	%)
WW		91		66		37.9	%		43.8	%		(5.9	%)
* See footnotes at end of document

REPORTED SALES vs. PRIOR PERIOD
$MM
	FIRST QUARTER
					% Change
	2009		2008		Reported			Operational (1)			Currency
MEDICAL DEVICES AND DIAGNOSTICS   (2) (3)
CORDIS (6)
US		246		342		(28.1	%)		(28.1	%)		-
Intl		422		459		(8.1	%)		(1.7	%)		(6.4	%)
WW		668		801		(16.6	%)		(12.9	%)		(3.7	%)
DEPUY
US		766		709		8.0	%		8.0	%		-
Intl		526		578		(9.0	%)		6.4	%		(15.4	%)
WW		1,292		1,287		0.4	%		7.3	%		(6.9	%)
DIABETES CARE
US		270		303		(10.9	%)		(10.9	%)		-
Intl		271		312		(13.1	%)		(1.3	%)		(11.8	%)
WW		541		615		(12.0	%)		(6.0	%)		(6.0	%)
ETHICON
US		405		341		18.8	%		18.8	%		-
Intl		548		604		(9.3	%)		3.7	%		(13.0	%)
WW		953		945		0.8	%		9.1	%		(8.3	%)
ETHICON ENDO-SURGERY
US		454		429		5.8	%		5.8	%		-
Intl		561		574		(2.3	%)		11.4	%		(13.7	%)
WW		1,015		1,003		1.2	%		8.6	%		(7.4	%)
ORTHO-CLINICAL DIAGNOSTICS
US		277		238		16.4	%		16.4	%		-
Intl		190		205		(7.3	%)		3.2	%		(10.5	%)
WW		467		443		5.4	%		10.3	%		(4.9	%)
VISION CARE
US		234		226		3.5	%		3.5	%		-
Intl		365		381		(4.2	%)		(1.1	%)		(3.1	%)
WW		599		607		(1.3	%)		0.6	%		(1.9	%)
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		2,652		2,588		2.5	%		2.5	%		-
Intl		2,883		3,113		(7.4	%)		3.6	%		(11.0	%)
WW		5,535		5,701		(2.9	%)		3.1	%		(6.0	%)
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Prior year amounts have been reclassified to conform with current presentation
(4) For external purposes, reported as U.S. sales
(5) Included in Other
(6) Includes sales of Drug-Eluting Stents for Q1 2009 of $68, $184 and $252 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q1 2008 of $169, $231 and $400 million Domestic, International and Worldwide respectively